During its latest fiscal year, BD reported its revenues dipping 1.4 percent as it made $19.1 billion in 2021 and raked in $18.9 billion in 2022.
The company attributed part of the loss to less demand for its COVID-19 diagnostic tests. Among its three main segments — medical, life sciences and interventional — BD’s life sciences sales fell 16.3 percent compared to last year’s figures because of dwindling demand for COVID-19 tests.
BD whittled its 2023 projected earnings for the tests to be between $125 million and $175 million — a sharp dropoff from 2022’s sales, which were $511 million.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
